Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU
Executive Summary
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
You may also be interested in...
‘A Divorce But We Weren’t Even Married’ – Swiss Medtech Expects No EU MRA Before May
A last-minute solution to the unresolved EU MRA issue is unlikely, so local manufacturers must prepare for Switzerland to be a “third country” to the EU after the MDR comes fully into force.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.